Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01689246 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 3 study, sponsored by TauRx Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 891
- Enrollment target
NCT01689246: Completed Phase 3 study, sponsored by TauRx Therapeutics.
NCT01689246 is a Phase 3 study that has completed, run by TauRx Therapeutics. The registered enrollment target is 891 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01689246, a Phase 3 study, has completed, sponsored by TauRx Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 891 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
Interventions
- DRUG Placebo
- DRUG TRx0237 150 mg/day
- DRUG TRx0237 250 mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 891 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
What the finished NCT01689246 record still lists
NCT01689246 is an interventional study that assigns participants to a tested intervention. The registered 891 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01689246 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01689246 about?
NCT01689246 is a clinical study titled "Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease". The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
What is the current status of trial NCT01689246?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 891 participants. The study started on 2013-01. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01689246?
The interventions under investigation include: Placebo (DRUG), TRx0237 150 mg/day (DRUG), TRx0237 250 mg/day (DRUG).
Who is sponsoring clinical trial NCT01689246?
This trial is sponsored by TauRx Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01689246's enrollment target sits among peer trials
891 364th of 2000 higher than 1,637 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05855200 · 892 participants · Phase 3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia